drugset / Trial / NCT06306040

Effect of Intravenous Nalbuphine and Magnesium Sulfate on Emergence Agitation in Pediatric

NCT06306040

Phase 3 Unknown 105 enrolled Assiut University
RandomizedParallel-groupSingle-blindPrevention

Summary

• Primary outcome: Measure The incidence of EA in children undergoing to hypospadias repair under general anesthesia is considered using Pediatric Anesthesia Emergence Delirium (PAED) scales. • Secondary outcome: * Therefore, we designed a prospective, randomized, double-blind, single center study to investigate whether nalbuphine and/or magnesium sulphate can prevent EA after hypospadias repair in children under general anesthesia. In addition, the characteristics of anesthesia recovery and the incidence of adverse effects will also be evaluated in this study. Post-operative extubating time, interaction time, open eye time and emergence time. incidence of post-operative vomiting (PONV), laryngospasm, breath-holding, coughing, oxygen desaturation, and cardiac arrhythmias. * Face, Legs, Activity, Cry and Consola Bility (FLACC) scale is used to determine post-operative pain score * Parental satisfaction scores

Timeline

Start
2024-04-02
Primary completion
2024-11-03
Completion
2025-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 30 mg/kg Intravenous
Subject Nalbuphine Small molecule 0.1 mg/kg Intravenous

Indications